Geode Capital Management
HSCS icon

Geode Capital Management’s Heart Test Laboratories HSCS Stock Holding History

Geode Capital Management’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.9K Sell
23,049
-5,889
-20% -$12.1K ﹤0.01% 4212
2026
Q1 		$71.2K Buy
28,938
+2,010
+7% +$5.86K ﹤0.01% 4226
2025
Q4 		$83.2K Buy
26,928
+14,150
+111% +$42K ﹤0.01% 4137
2025
Q3 		$44.5K Buy
12,778
+1,179
+10% +$4.29K ﹤0.01% 4317
2025
Q2 		$43.5K Buy
+11,599
New +$40.6K ﹤0.01% 4242
2024
Q2 		– Sell
-423
Closed -$4.95K – 4601
2024
Q1 		$4.95K Hold
423
– – ﹤0.01% 4586
2023
Q4 		$7.24K Hold
423
– – ﹤0.01% 4617
2023
Q3 		$18.3K Buy
+423
New +$32.8K ﹤0.01% 4637

Other funds holding HSCS

TA
TFB Advisors Overland Park, Kansas $227M AUM 26.47% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management's HSCS Position: Q2 2026 in Review

Geode Capital Management reduced its Heart Test Laboratories (HSCS) stake by 20% in Q2 2026, selling an estimated $12.1K and leaving 23,049 shares worth $57.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4212.

Geode Capital Management first reported a position in HSCS in Q3 2023 and has held it in 8 quarters since. The position peaked at $83.2K in Q4 2025. 16 funds tracked by Wall St. Rank hold HSCS as of Q2 2026.

  • Geode Capital Management held 23,049 shares of Heart Test Laboratories worth $57.9K as of Q2 2026.
  • Geode Capital Management sold 5,889 Heart Test Laboratories shares in Q2 2026, an estimated $12.1K.
  • Heart Test Laboratories made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4212 holding.
  • Geode Capital Management first reported a position in Heart Test Laboratories in Q3 2023 and has held it in 8 quarters since.
  • Geode Capital Management's Heart Test Laboratories position peaked at $83.2K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.